
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MOD-246
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : $1,330.0 million
Deal Type : Acquisition
Modifi Biosciences Acquired by Merck
Details : Through the acquisition, Merck will utilize Modifi's scientific expertise and oncology product pipeline, which includes MOD-246, a small molecule currently being evaluated for glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $30.0 million
October 23, 2024
Lead Product(s) : MOD-246
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : $1,330.0 million
Deal Type : Acquisition

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Connecticut Innovation
Deal Size : $10.7 million
Deal Type : Financing
Modifi Bio Raises Additional $4.3 Million in Seed Funding
Details : The financing will be used to further advance Modifi bio's lead molecules towards IND-enabling studies and phase I clinical trials. It works in DNA modification as a novel approach to target cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 16, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Connecticut Innovation
Deal Size : $10.7 million
Deal Type : Financing

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : $2.4 million
Deal Type : Funding
Details : The grant will support drug development around a class of molecules targeting cancer cells lacking expression of key DNA repair protein called MGMT (O6-methylguanine methyl transferase), based on a recent publication from the Yale founders’ laboratorie...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 25, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : $2.4 million
Deal Type : Funding
